Longterm renal outcome after 10 years enzyme replacement therapy with agalsidase A in Fabry male patients

被引：0
|
作者：
Karabul, Nesrin [1 ]
Arash, Laila [1 ]
Waechter, Maike [1 ]
Beck, Michael [1 ]
Kampmann, Christof [1 ]
Mengel, Eugen [1 ]
机构：
[1] Villa Metabol, Mainz, Germany
来源：
MOLECULAR GENETICS AND METABOLISM | 2014年 / 111卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2013.12.130
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
118
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [41] Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease
    Kim, Il Young
    Lee, Hyun Jung
    Cheon, Chong Kun
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2021, 40 (04) : 611 - 619
  • [42] Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease
    Lubanda, Jean-Claude
    Anijalg, Ene
    Bzduch, Vladimir
    Thurberg, Beth L.
    Benichou, Bernard
    Tylki-Szymanska, Anna
    GENETICS IN MEDICINE, 2009, 11 (04) : 256 - 264
  • [43] Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha
    Tanaka, Akemi
    Takeda, Taisuke
    Hoshina, Takao
    Fukai, Kazuyoshi
    Yamano, Tsunekazu
    JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 : S249 - S252
  • [44] Effect of enzyme replacement therapy on clinical outcome in patients with Fabry disease
    Breunig, FB
    Knoll, A
    Weidemann, F
    Strotmann, J
    Wanner, C
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V246 - V247
  • [45] Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease
    Lenders, Malte
    Schmitz, Boris
    Stypmann, Joerg
    Duning, Thomas
    Brand, Stefan-Martin
    Kurschat, Christine
    Brand, Eva
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (12) : 2090 - 2097
  • [46] Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
    Beck, Michael
    Hughes, Derralynn
    Kampmann, Christoph
    Larroque, Sylvain
    Mehta, Atul
    Pintos-Morell, Guillem
    Ramaswami, Uma
    West, Michael
    Wijatyk, Anna
    Giugliani, Roberto
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S19 - S20
  • [47] Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
    Beck, Michael
    Hughes, Derralynn
    Kampmann, Christoph
    Larroque, Sylvain
    Mehta, Atul
    Pintos-Morell, Guillem
    Ramaswami, Uma
    West, Michael
    Wijatyk, Anna
    Giugliani, Roberto
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2015, 3 : 21 - 27
  • [48] Renal function in patients with fabry disease on enzyme replacement therapy (ERT)
    West, Michael
    Cybulla, Markus
    Feriozzi, Sandro
    Schwarting, Andreas
    Schiffmann, Raphael
    Mehta, Atul
    Sunder-Plassmann, Gere
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 13 - 13
  • [49] Enzyme replacement therapy and renal function in 201 patients with Fabry disease
    Schwarting, A.
    Dehout, F.
    Feriozzi, S.
    Beck, M.
    Mehta, A.
    Sunder-Plassmann, G.
    CLINICAL NEPHROLOGY, 2006, 66 (02) : 77 - 84
  • [50] Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data
    Dehout, F
    Schwarting, A
    Beck, M
    Mehta, A
    Ricci, R
    Widmer, U
    ACTA PAEDIATRICA, 2003, 92 : 14 - 15
12345